Thailand Peptides
Get in Contact
Catalog
PeptidesCategories
Research
CompareInformation
Calculator
Get in Contact
Comparison · GH Secretagogue

Hexarelin vs Ipamorelin

Hexarelin and Ipamorelin are both ghrelin-receptor agonists (GHS-R1a) but sit on opposite sides of the potency-versus-selectivity trade-off. Hexarelin wins on raw GH-release magnitude. Ipamorelin wins on endocrine cleanliness and tolerability for extended cycles.

Bangkok research desk ·

Side-by-side

Hexarelin Ipamorelin
MechanismHexapeptide GHS; potent non-selective ghrelin-receptor agonist.Selective GHS-R1a agonist; minimal cortisol or prolactin effect.
Half-lifeShort.~2 hours.
Dose100 mcg × 2-3 daily SC.200-300 mcg × 2-3 daily SC.
Cycle4-8 weeks.12 weeks on / 4 off.
Research contextStrong acute GH release; cortisol and prolactin elevation1.Selective GH release; minimal off-target endocrine effects2.
Cost tierLow-to-mid.Low-to-mid.

Hexarelin and Ipamorelin both activate GHS-R1a, the ghrelin receptor. The difference is in what else they activate. Hexarelin produces the strongest acute GH release in the class but also elevates cortisol and prolactin, and it stimulates appetite via ghrelin-like activity1. Ipamorelin was specifically engineered to avoid those off-target activities; its selectivity profile is the reason it became the default GHS pairing in extended research cycles2.

The practical consequence shows up in cycle length. Hexarelin protocols run 4-8 weeks because receptor desensitisation accelerates with the higher potency and because the cortisol/prolactin profile compounds over time. Ipamorelin supports 12-week cycles because its cleaner profile does not accumulate endocrine noise. Daily dose timing is similar for both (2-3 injections spread across the day) because neither compound maintains a long circulating half-life.

Research protocols select Hexarelin when the endpoint is acute GH-release capacity, pituitary responsiveness in elderly or compromised populations, or short-term pulse amplitude studies. Ipamorelin wins when the protocol is extended, when IGF-1 elevation is wanted without cortisol interference, or when the researcher intends to pair a GHS with a GHRH analog for the canonical complementary-pathway stack. See the GH secretagogue cycle design for the full class view.

Frequently asked

Why pick Hexarelin over Ipamorelin?
Acute GH-release magnitude. Hexarelin is more potent on a per-dose basis. Research protocols that need the strongest short-window GH pulse select Hexarelin; those needing sustainable cycle length select Ipamorelin.
Does Hexarelin cause cortisol issues?
Compared to selective GHS such as Ipamorelin, yes. Hexarelin elevates cortisol and prolactin more than Ipamorelin2. Research protocols should account for this in cycle planning.
Can either be stacked with CJC-1295?
Both can be, but Ipamorelin is the more common research pairing because the sustained-tone-plus-pulsatile-release logic does not need the extra endocrine activity that Hexarelin carries.
Research desk
Ordering both Hexarelin and Ipamorelin for a research protocol? The Bangkok desk handles pricing, COA, and timing on WhatsApp.
Open a line with the research desk ≥98% HPLC purity · supplier COA on file · Bangkok-based

Go deeper

Related comparisons

References

  1. Ghigo E, et al. Growth hormone-releasing activity of hexarelin. J Clin Endocrinol Metab. 1994. PMID: 8126144
  2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID: 9849822

All references verified against PubMed via NCBI E-utilities.